SCHEMBL2424533

SCHEMBL2424533

CS(=O)(=O)N1CCC(Nc2cc(-c3cccc(C#N)c3)cc3ccncc23)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 2/20 0.43
IDO1 P14902 1/20 0.42
NPY5R Q15761 1/20 0.42
CCNT1 O60563 2/20 0.41
CDK9 P50750 2/20 0.41
DYRK1A Q13627 1/20 0.41
IRAK4 Q9NWZ3 1/20 0.40
PRKCZ Q05513 5/20 0.40
PRKD2 Q9BZL6 4/20 0.40
CDK2 P24941 2/20 0.39
CDK1 P06493 1/20 0.39
CDK4 P11802 1/20 0.39
CCNB1 P14635 1/20 0.39
CCND1 P24385 1/20 0.39
CCNE1 P24864 1/20 0.39
CCND3 P30281 1/20 0.39
CDK7 P50613 1/20 0.39
CCNH P51946 1/20 0.39
MNAT1 P51948 1/20 0.39
CDK6 Q00534 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13087305 0.95 ROCK2 (0.46) ROCK2IDO1NPY5RCCNT1CDK9
SCHEMBL13087361 0.95 ROCK2 (0.46) ROCK2IDO1NPY5RCCNT1CDK9
SCHEMBL13087712 0.92 ROCK2 (0.45) ROCK2PRKCZPRKD2CDK2CCNA2
SCHEMBL13089969 0.91 ROCK2 (0.43) ROCK2IRAK4PRKCZPRKD2CDK2
SCHEMBL13087334 0.91 ROCK2 (0.41) ROCK2CCNT1CDK9IRAK4PRKCZ
SCHEMBL13087706 0.91 ROCK2 (0.42) ROCK2IRAK4PRKCZPRKD2CDK2
SCHEMBL13087539 0.90 DYRK1A (0.42) ROCK2IDO1CCNT1CDK9DYRK1A
SCHEMBL13087640 0.90 CCR6 (0.46) IDO1CCNT1CDK9DYRK1AIRAK4
SCHEMBL13087596 0.89 DYRK1A (0.41) ROCK2IDO1CCNT1CDK9DYRK1A
SCHEMBL13090008 0.89 CCR6 (0.51) ROCK2CDK2CCNA2CCR6GPR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2366699-B1 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF ASAHI KASEI PHARMA CORP (JP) 2013-08-07 EP disclosed
US-8299055-B2 8-substituted isoquinoline derivative and the use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2012-10-30 US disclosed
US-8299055-B2 8-substituted isoquinoline derivative and the use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2012-10-30 US disclosed
US-8299055-B2 8-substituted isoquinoline derivative and the use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2012-10-30 US disclosed
EP-2366699-A1 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2011-09-21 EP disclosed
US-20100261701-A1 8-Substituted isoquinoline derivative and the use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2010-10-14 US disclosed
US-20100261701-A1 8-Substituted isoquinoline derivative and the use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2010-10-14 US disclosed
US-20100261701-A1 8-Substituted isoquinoline derivative and the use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2010-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100261701-A1 8-Substituted isoquinoline derivative and the use thereof RELA, NFKBIA, NFKB2 ROCK2 1065/4885IDO1 514/4885NPY5R 3761/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.